BioSpace News Archive

Alnylam Pharmaceuticals, Inc. announced today that management will present a company overview at the Stifel 2022 CNS Days, being held virtually, on Monday, March 28, 2022 at 2:00 pm ET

Goldfinch Bio today announced that it will host a virtual event to discuss the unmet need in focal segmental glomerular sclerosis (FSGS), as well as the recently announced clinical data from TRACTION-2, the ongoing Phase 2 trial evaluating GFB-887 as a precision medicine for the treatment of FSGS. GFB-887 is a podocyte-targeting, small molecule inhibitor of Transient Receptor Potential Canonical Channel 5 (TRPC5).

Aldeyra Therapeutics, Inc. today announced that it will host a Research & Development Day from 10:00 a.m. to 12:30 p.m. ET on Tuesday, March 29, 2022 in New York City.

ENDRA Life Sciences Inc. today announced that the company will report financial results for the fourth quarter of 2021 on Wednesday, March 30, 2022 after the close of trading on the U.S. financial markets.

Spago Nanomedical AB will present a poster summarizing its platform technology for precision imaging and therapy at the scientific conference ACS Spring 2022, which is held digitally on March 20-24.

BioCorRx Inc., a developer and provider of innovative treatment programs for substance abuse and related disorders, announced that management will be participating in two upcoming conferences.

InnoSIGN, a precision medicine company, announced that it raised an $8M Series A financing.

AppliedVR, a pioneer advancing the next generation of immersive therapeutics, today announced a new name for its flagship virtual reality (VR) therapeutic.

Vivalink, a leading provider of digital healthcare solutions, is providing its Biometric Data Platform to help detect neutropenic fever events.

Dr Alterman is currently an Assistant Professor at the RNA Therapeutics Institute, UMass Chan Medical School, where she focuses on siRNA chemical modification for extra-hepatic delivery.